GLP-1 & Weight Loss stocks on X

GLP-1 & Weight Loss stocks trending on X

Top stocks by X chatter

Pfizer Inc.$PFEStrong Fundamentals

Drug Manufacturers - General

$28.46+1.79%

1Y+13.9%

657 posts-0%

Mixed sentiment

The conversation on Pfizer is split between yield hunters and pipeline skeptics. Bulls cite the fresh FDA approval of the XFG-adapted COVID vaccine with BioNTech, a 6% dividend, falling debt, and a 9x multiple; skeptics dwell on the 2033 patent cliff, questions around the Vesper 3 obesity trial, and past discontinuations of oral GLP-1 programs. Unusual puts and Morgan Stanley notes on adjacent immunology add technical noise.

Comeback attempt

Pfizer is the mega-cap pharma still working through the post-COVID demand cliff, with a maturing pipeline and a maligned M&A track record. What makes right now different is a rare cluster of open-market insider buying, coincident with a genuine near-term catalyst. Why the setup is worth attention: • The insider buying is unusually clean: CEO Albert Bourla, director Mortimer Buckley, and director Ronald Blaylock each open-market bought ~$1M in the current window — a real-cash cluster (not tax-withholding or option exercises) at 85% of the 52-week range is where such buys carry the most information. • The dated catalyst is real: the FDA just approved the 2026-27 COVID vaccine from Pfizer/BioNTech for the high-risk population, locking in a defensible revenue line into winter — smaller than peak years, still a multi-billion-dollar franchise. • The valuation is defensible: 20x earnings, 12x EV/EBITDA and a 6.4% FCF yield with a ~7% dividend on top — for a business earning a 23% operating margin, the market is pricing Seagen-style skepticism, and any pipeline win compresses that discount. • The pipeline is showing life: the NVCT + PFE Lorla ALK combo trial is recruiting; the minority M&A worry (Seagen, Metsera) is fair and pipeline data would blunt it. The November 3 print sets the tone — a clean Seagen-integration update plus vaccine-season contribution keeps the rerate going; a pipeline setback or a guide cut breaks the setup and turns the insider buys into noise.

Eli Lilly and Company$LLYStrong Fundamentals

Drug Manufacturers - General

$1,157.83-1.43%

1Y+57.5%

1,181 posts-1%

Mixed sentiment

Genuinely split. Bulls celebrate FDA approval of Mounjaro to 'reduce cardiovascular risk' in high-risk T2D adults, a UK Foundayo launch, an Alzheimer's blood-test nod, and long-term $1,800 targets. Bears highlight PepsiCo dropping GLP-1 coverage, Foundayo prescriptions running well behind Novo's Oral Wegovy launch pace, an active $NKTR lawsuit heading to jury on Sept 8, and a chartist calling Wave V complete and staying 'fully short.' Retatrutide's biologic-reclassification suit sits as the swing catalyst.

Proven numbers

Eli Lilly is the leading GLP-1 franchise in global pharma — Mounjaro (tirzepatide) for type-2 diabetes and Zepbound for obesity are the biggest new pharmaceutical launch cycle since the statins. The stock had gone sideways for most of 2026 before a fresh breakout above the $1,232 base on the back of an FDA approval that widens the addressable population. • Growth is not just holding, it's genuinely enormous: Q1 revenue grew 55% year-over-year to $19.8B with 45% operating margins and an 82% gross margin — every one of the last four EPS prints beat consensus by 9-31%, and consensus already models 100%+ EPS growth to FY28. • The Aug 28 FDA approval matters more than the tape suggests: Mounjaro is now approved to reduce cardiovascular risk in high-risk type-2 diabetics — that expands prescribing rationale beyond glycemic control, moves Medicare and commercial coverage decisions, and preempts the pricing pressure that competitors were relying on. • Real-world evidence is doing the second job: fresh data shows Zepbound reducing downstream healthcare costs, which is what payer contracts need to justify formulary coverage — a soft catalyst, but one that shows up as durable prescription volume, not a one-time headline. • Insider tape is mildly negative: several officers sold $2-7M each in August (Jonsson $7.6M, Hakim $6.0M, Zakrowski $2.4M) — real dollars, but small against a $1.1T market cap; not a warning, just a reminder senior management sees fair value here. The path if the run continues is Q3 confirming the Mounjaro-CV script uptake and any interim orforglipron oral-GLP-1 data being clean — the multiple accepts durable 40%+ revenue growth well into FY27 and the tape gets its next leg. What breaks the run is a competitive read from NKTR's Sept 8 trial or fresh orforglipron liver-enzyme concerns that force a label revision — that's the specific catalyst the crowd is watching for a good reason.

Danaher Corporation$DHRStrong Fundamentals

Medical - Diagnostics & Research

$213.56-1.16%

1Y+4.8%

87 posts+6%

Bullish sentiment

Danaher posters cheer the CEO change (Julie in, 'Eeyore' out) as a +2% AH reaction, with DHR appearing on liquid-leader watchlists and technical accumulation setups. Some Rales-family equity-grant frustration. Sentiment is broadly bullish on the leadership refresh.

Proven numbers

Danaher Corporation is a leading life-sciences and diagnostics conglomerate — Beckman Coulter, Cepheid, Cytiva, Leica, Radiometer, plus the Environmental & Applied Solutions segment. The setup is a real-business quality name coiled on a specific leadership catalyst. • The CEO change is the specific catalyst: Danaher announced August 3 that its Board appointed Julie Sawyer Montgomery as President and CEO effective October 1 — the crowd is cheering the change ("Julie in, 'Eeyore' out") as +2% AH reaction and DHR is appearing on liquid-leader watchlists with technical-accumulation setups. • The core P&L is compounding as expected: Q1 revenue grew 3.7% YoY to $5.95B at a 60% gross margin and 23% operating margin, Q2 EPS beat at $1.94 vs $1.85 consensus, and the sell side models FY26 EPS at ~$8.49 rising to ~$10.16 in 2028 — mid-single-digit revenue growth with mid-teens EPS growth from margin expansion. • The Rales-family equity-grant tape is genuine: Steven and Mitchell Rales each received 1.5M shares in an A-Award on August 4 (worth ~$195M each), and Jonathan Leiken received a $17.9M A-Award — combined a very large equity award to the founding family plus C-suite that some in the sample flagged as frustrating, but is likely tied to the CEO transition compensation planning. The setup is a real-business quality life-sciences compounder coiled on the CEO transition plus the recent Bamco 315,789-share purchase — the October 20 Q3 print is the referee, and the market needs continued mid-single-digit revenue growth plus updated Biotechnology segment strength. A clean beat plus a first Montgomery-led guidance framing extends the coil up toward $240; a soft Biotechnology or Diagnostics segment print cools the tape from current levels.

Thermo Fisher Scientific Inc.$TMOStrong Fundamentals

Medical - Diagnostics & Research

$617.1-0.82%

1Y+26.6%

96 posts+2%

Bullish sentiment

Bullish tape on Thermo Fisher and lab-tools peers. TMO is now roughly flat on the year after a ~25% drawdown, with peers DHR and AVTR hitting multi-month highs. Bulls frame this as the 'best Q of the year' for traditional-tools names on sandbagged Q2 guides and easy pharma/academic R&D comps. Dominant tone is thesis intact.

Agilent Technologies, Inc.$A

Medical - Diagnostics & Research

$153.63-0.14%

1Y+22.7%

142 posts+14%

Bullish sentiment

X leans bullish, driven by Agilent's Q3 print — a $0.13 beat, 8% revenue growth and a third straight FY guidance raise. Traders flag a five-year base breakout with 28.3% non-GAAP operating margins as the standout, and pass around a Jefferies $150 price target hike. Compounder-focused accounts pair the print with a solid Waters report and call healthcare worth another look.

Fractyl Health, Inc.$GUTS

Biotechnology

$0.711+7.86%

1Y-27.2%

9 posts-11%

Bullish sentiment

Fractyl Health reports positive REMAIN-1 midpoint cohort data showing durable weight maintenance one year after GLP-1 discontinuation. H.C. Wainwright reiterates Buy PT $8, Morgan Stanley PT $2, with pivotal cohort data expected early Q4 and potential De Novo FDA submission late Q4. Approval seen ~80% derisked.

Hims & Hers Health, Inc.$HIMS

Medical - Equipment & Services

$29.58+2.57%

1Y-28.8%

1,791 posts-1%

Mixed sentiment

Mixed with heavy volume on both sides. Bulls anchor on a $262M CalSTRS buy, ~96% institutional ownership, Truist's call that compounded GLP-1s will drive most 2026 US GLP-1 revenue, and Eucalyptus's Wegovy-pill launch in Germany. Bears cite Visa placing HIMS into an "Acquirer monitoring program," a $2.2M put order, and a chartist calling it "not a bullish chart" after an ~8% Visa-headline drop. Camps explicitly disagree.

Viking Therapeutics, Inc.$VKTX

Biotechnology

$32.78+1.93%

1Y+19.2%

215 posts-5%

Bullish sentiment

Anticipation is high heading into a Phase 2 maintenance readout for VK2735, with posters citing a slower Phase 3 titration and calling 18-19% weight loss at 21 weeks the sweet spot for a rerating. Adds around $32-34 are shared as risk/reward is 'ridiculous,' oral pill optionality remains, and traders eye a Moderna-style short cover. Some fret about GI tolerability but few see the data disappointing.

Repligen Corporation$RGEN

Medical - Instruments & Supplies

$180.98+2.67%

1Y+50.0%

28 posts0%

Bullish sentiment

Repligen delivered Q2 earnings raising both FY26 organic revenue growth guidance to 10.5%-13.5% and adjusted EPS. RGEN is acquiring BioLife Solutions for $1.5B — expanding cell therapy capabilities. Bulls describe RGEN as taking bioprocessing share while DHR remains challenged. Bearish voices are essentially absent.

Structure Therapeutics Inc.$GPCR

Biotechnology

$45.91-3.08%

1Y+128.6%

31 posts+8%

Bullish sentiment

Structure Therapeutics is being framed as a next-leg-higher obesity/GLP-1 play. Cantor and Piper Sandler both reiterated Overweight on Viking Therapeutics with GPCR named in the same peer set alongside LLY and NVO, and a Chinese small-molecule GLP-1 competitor is being cross-analyzed as validation of the space rather than a direct threat. Retail voices are more emphatic, calling for a run toward $100 or a buyout given repeated tests of overhead resistance on light volume, though the sample is thin.

Kailera Therapeutics, Inc.$KLRA

Biotechnology

$15.40-5.00%

1Y-40.8%

22 posts+10%

Bullish sentiment

Kallyope Therapeutics chatter is quietly bullish. Royalty Pharma Sub-Manager and Atlas Venture Life Science Advisors both opened new positions in Q2, and KLRA appears on a list of biopharma names with the largest net increases in specialist holders. A minority notes a 1.4% Phase 3 discontinuation rate hides a 19.9% dose reduction rate at 6mg due to TEAEs. Tone is small but confident specialist-holder accumulation.

Merck & Co., Inc.$MRK

Drug Manufacturers - General

$147.76-0.40%

1Y+72.9%

1,753 posts+3%

Bullish sentiment

Merck sits at all-time highs and the tape is celebratory, powered by the Moderna-partnered intismeran Phase 3 melanoma win, which a TD Cowen KOL calls "practice-changing" if RFS HR stays below 0.70. Posters flag it as SCHD's new #1 holding and a dividend king, with Wolfe modeling $9.2B peak sales across four indications. Longer-horizon skeptics flag the pharma patent cliff through 2033 as an overhang.

Rhythm Pharmaceuticals, Inc.$RYTM

Biotechnology

$106.13-0.97%

1Y+1.8%

20 posts+5%

PendingInsufficient posts on X for reliable sentiment analysis.

Novo Nordisk A/S$NVO

Drug Manufacturers - General

$45.33-0.61%

1Y-19.6%

509 posts-2%

Mixed sentiment

Discussion is mixed on Novo Nordisk, with camps openly disagreeing. Bulls anchor on a "textbook accumulation" thesis at 13-15x forward P/E, JPMorgan's raise to DKK 275, an FDA appeals-court win against compounders, and Oral Wegovy dominating Lilly's Foundayo (~175K vs ~40K weekly scripts). Bears cite Deutsche Bank's Sell downgrade, PepsiCo dropping GLP-1 coverage, absent insider buying, and calls of a "value trap" as Lilly extends its lead.

Septerna Inc$SEPN

Biotechnology

$38.15-1.95%

1Y+209.2%

13 posts0%

PendingInsufficient posts on X for reliable sentiment analysis.

Altimmune, Inc.$ALT

Biotechnology

$3.110.00%

1Y-17.1%

1,875 posts+15%

Bullish sentiment

The conversation is entirely about the AltLayer crypto token, not any equity — the dominant thread is bullish, celebrating buyback-and-burn rounds 7 and 8 (now over 3% of supply retired) and flagging ALT as one of the top HyperEVM restaked-rollup plays. A dissenting post lumps it into a "raised $22.8M, -99% from ATH" pivot-history critique, and one whale-tracker flags coordinated exits.

Amgen Inc.$AMGN

Drug Manufacturers - General

$429.88-0.59%

1Y+49.8%

197 posts-1%

Bullish sentiment

Chatter is thin but skewed bullish, driven almost entirely by Amgen's positive Phase 3 readout for Tezspire in eosinophilic esophagitis, which met both co-primary and all key secondary endpoints. Several posts flag Amgen making fresh S&P 500 all-time highs and its position in the emerging Lp(a) cardiovascular drug race. Deeper commentary muses on oncology M&A candidates and raises lingering questions about GIP antagonism in the MariTide obesity program.

IQVIA Holdings Inc.$IQV

Medical - Diagnostics & Research

$261.19-0.21%

1Y+42.2%

47 posts+7%

Bullish sentiment

IQVIA's Q2 print was a beat-and-guide-in-line — EPS $3.15 vs $3.03 (+$0.12), revenue beat with guidance raised on the back of stronger R&D bookings. IQV is being pitched as one of four public companies with the biggest collections of anonymized healthcare data (alongside UNH, VEEV and TEM). MEDP is being called a positive read-through for IQV within the CRO/tools basket. There's no bearish voice in this window.

Novo Nordisk A/S$NONOF

Drug Manufacturers - General

$45.248+0.51%

1Y-20.2%

0 posts

PendingInsufficient posts on X for reliable sentiment analysis.

Bachem Holding AG$BCHMF

Drug Manufacturers - Specialty & Generic

$91.000.00%

1Y+48.1%

0 posts

PendingInsufficient posts on X for reliable sentiment analysis.

Medtronic plc$MDT

Medical - Devices

$90.65-0.64%

1Y-2.9%

471 posts-9%

Mixed sentiment

Chatter fractures across two assets sharing the ticker. Substantive equity mentions cite a Mizuho $100 base-case PT on Hugo/RDN growth, an earnings watch alongside PANW and AVGO, and dry humor about peer cyber-attacks ('AI probably has no idea what to do with whatever spaghetti monster IT system MDT has'). The louder crowd is celebrating a 'Measurable Data' crypto token up 292%-552%, unrelated to Medtronic.